The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

cellcura.com

Stage

Incubator/Accelerator | Alive

About CellCura

CellCura, Inc. is a company dedicated to the development of equipment and products for use in assisted reproductive technology (ART) and stem cell research.

CellCura Headquarter Location

Madison, Wisconsin, 53701,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CellCura

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CellCura is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

CellCura Patents

CellCura has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/14/2014

Embryologists, Fertility medicine, Expert systems, Embryology, Fertility

Application

Application Date

3/14/2014

Grant Date

Title

Related Topics

Embryologists, Fertility medicine, Expert systems, Embryology, Fertility

Status

Application

Latest CellCura News

Cellcura ASA : Announces Financial Report Q3 2014

Nov 28, 2014

(You can enter multiple email addresses separated by commas) Message : Q3 AND SUBSEQUENT EVENTS CellCura's cost cutting programme described in recent reports was completed with full effect as at the end of Q2. Short term financial constraints remain an issue and the company has been relying on shareholder loans to meet its financial obligations. After the balance sheet date shareholders have extended further loans of NOK 0.78 million which are not reflected in the financials as at the end of Q3. Also, the company has been in dialogue with Innovation Norway and has been granted a deferral of instalments, with subsequent extension of maturities to the respective loan facilities. Due to the size of outstanding loans and in an effort to secure more time to resolve the long-term financing of the Company, CellCura's shareholders resolved in an Extraordinary General Meeting 21 November 2014 to issue a convertible loan covering all outstanding shareholder loans including accrued interest as of 31 October 2014 owed to the largest shareholder, Dag Dvergsten AS, as well as securing new funding of NOK 1.5 million . This does not constitute a viable long-term financing solution and Management and the Board of Directors will need to put in place an alternative financing solution by the end of 2014. Short term financial constraints remain an issue and the company has been relying on shareholder loans to meet its financial obligations. After the balance sheet date shareholders have extended further loans of NOK 0.78 million which are not reflected in the financials as at the end of Q3. Also, the company has been in dialogue with Innovation Norway and has been granted a deferral of instalments, with subsequent extension of maturities to the respective loan facilities. Due to the size of outstanding loans and in an effort to secure more time to resolve the long - term financing of the Company, CellCura's shareholder s resolved in an Extraordinary General Meeting 21 November 2014 to issue a convertible loan covering all outstanding shareholder loans including accrued interest as of 31 October 2014 owed to the largest shareholder, Dag Dvergsten AS, as well as securing new funding of NOK 1.5 million . The total conver tible loan balance at issuance is NOK 12.05 million carrying an interest rate of 7.5% and maturing at the end of 2017. The convertible loan and any accrued interest can be converted into shares at NOK 0.20 /share, in total representing more than 60 million shares if converted in full as at issuance, and more if converted after accruing further interest. This resolution has provided the company with an adequate short - term liquidity. However, this does not constitute a viable long - term financing solution and M anagement and the Board of Directors will need to put in place an alternative financing solution by the end of 2014. High lights - CellCura ART Lab Solution CellCura has continued to focus on expanding the existing customers' solutions with new modules in order to cover more of the processes in the clinics. Highlights - CellCura PFM The company continues to work on growing sales in unregulated markets and have already signed and expect to sign new distributor agreements in SE Asia . This will allow the compa ny to further develop its sales and distribution platform ahead of introducing products to regulated markets once the CE approval is in place. OPERATIONAL REVIEW CellCura develops, manufactures and sells products for the ART and stem cell industry. The offerings are as follows: CellCura Protein Free Media - A new unique and completely safe range of protein free cell culture media products that reduce risk and improve efficiency in the in vitro fertilization and embryo cultivation process . CellCura has established the subsidiary CellCura PFM AS to manage th e sales and marketing activities of the CellCura PFM products , currently distributed in unregulated markets. CellCura ART Lab Solution - A completely new generation of integrated laboratory and software solutions that secures a safe, controlled environme nt and ergonomic performance of cellular treatments in fertility clinics , as well as unrivalled safety, q uality assurance, workflow controls and login of work performed. The company is furthermore working on expanding the existing customers' solutions with new modules in order to cover more of the processes in the clinics. This enables our customers to f urther utilise the unique image based platform with integrated software offered by the CellCura Lab Solution and further exploit the transition from traditional equipment to this new generation lab solution. FINANCIAL REVIEW The revenue for third quarter 2014 was NOK 0 . 4 million compared with NOK 2 . 4 million in the third quarter of 2013 . The Groups operating expenses for the third quarter 201 4 was NOK 3 . 7 million compared to NOK 7 . 9 million in the third quarter of 201 3 . Net loss during the third quarter of 201 4 was NOK 4

  • Where is CellCura's headquarters?

    CellCura's headquarters is located at Madison.

  • What is CellCura's latest funding round?

    CellCura's latest funding round is Incubator/Accelerator.

  • Who are the investors of CellCura?

    Investors of CellCura include MGE Innovation Center.

  • Who are CellCura's competitors?

    Competitors of CellCura include ViaCyte, Primorigen Biosciences, Kempbio, Guava Technologies, BioSilta and 11 more.

You May Also Like

I
IntelCell

IntelCell markets a product platform engineered to modernize research techniques for cell and tissue growth. The company's first product, Cell Drive, replaces traditional cell culture equipment by providing an unprecedented level of usability and sophistication for the user. For scientists whose research depends upon live cell culture, Cell Drive aims to offer a compact, precision, cell growth system that increases experimental control, aims to improve sterility, aims to provide digitization of data and methods, and aims to reduce human error and labor costs.

B
BioSilta

BioSilta, founded in 2007 in Oulu, Finland, utilizes its unique, proprietary EnBase technology platform to develop innovative, reagent-based EnPresso growth systems. When compared to conventional growth media, these growth systems significantly increase the yield of high quality biomolecules from microbial cultures.

DC Biosciences Logo
DC Biosciences

DC Biosciences, formerly Dundee Cell Products, provides pharmaceutical and biotech companies with novel technologies and proteomics services to accelerate the development of safer drugs.

P
Plectix Biosystems

Plectix BioSystems Inc. is focussed on approaches for overcoming challenges faced by biologists in the complex world of cell signaling.

C
CellAura Technologies

CellAura Technologies is a spin out company from the University of Nottingham, combining world-renowned expertise in the fields of synthetic chemistry and molecular pharmacology to produce high quality fluoresent G-protein coupled receptor ligands for use in molecular pharmacology and imaging at the single cell level.

A
AlphaGenix

AlphaGenix is a life science company located in Sioux Falls, SD that aims to develop products and technologies for basic and clinical research with a particular emphasis on stem cell biology, biomaterials and regenerative medicine. AlphaGenix sells its products non-exclusively through a world-wide network of companies. Its biomaterials, stem cell antibodies and kits are sold exclusively world-wide by Sigma-Aldrich

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.